Cargando…

Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)

The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug. Over the last ten years, the number of poorly soluble drugs has steadily increased. One of the progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaculikova, Eliska, Grunwaldova, Veronika, Kral, Vladimir, Dohnal, Jiri, Jampilek, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268062/
https://www.ncbi.nlm.nih.gov/pubmed/23132139
http://dx.doi.org/10.3390/molecules171113221
_version_ 1783376203845992448
author Vaculikova, Eliska
Grunwaldova, Veronika
Kral, Vladimir
Dohnal, Jiri
Jampilek, Josef
author_facet Vaculikova, Eliska
Grunwaldova, Veronika
Kral, Vladimir
Dohnal, Jiri
Jampilek, Josef
author_sort Vaculikova, Eliska
collection PubMed
description The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug. Over the last ten years, the number of poorly soluble drugs has steadily increased. One of the progressive ways for increasing oral bioavaibility is the technique of nanoparticle preparation, which allows many drugs to thus reach the intended site of action. Candesartan cilexetil and atorvastatin, belonging to class II of the biopharmaceutical classification system, were chosen as model active pharmaceutical ingredients in this study. Forty samples were prepared either by antisolvent precipitation/solvent evaporation method or by the emulsion/solvent evaporation technique with various commonly used surface-active excipients as nanoparticle stabilizers. All samples were analyzed by means of dynamic light scattering. The particle size of the determined 36 nanoparticle samples was to 574 nm, whereas 32 samples contained nanoparticles of less than 200 nm. Relationships between solvents and excipients used and their amount are discussed. Based on the results the investigated solvent evaporation methods can be used as an effective and an affordable technique for the preparation of nanoparticles.
format Online
Article
Text
id pubmed-6268062
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62680622018-12-13 Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†) Vaculikova, Eliska Grunwaldova, Veronika Kral, Vladimir Dohnal, Jiri Jampilek, Josef Molecules Article The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug. Over the last ten years, the number of poorly soluble drugs has steadily increased. One of the progressive ways for increasing oral bioavaibility is the technique of nanoparticle preparation, which allows many drugs to thus reach the intended site of action. Candesartan cilexetil and atorvastatin, belonging to class II of the biopharmaceutical classification system, were chosen as model active pharmaceutical ingredients in this study. Forty samples were prepared either by antisolvent precipitation/solvent evaporation method or by the emulsion/solvent evaporation technique with various commonly used surface-active excipients as nanoparticle stabilizers. All samples were analyzed by means of dynamic light scattering. The particle size of the determined 36 nanoparticle samples was to 574 nm, whereas 32 samples contained nanoparticles of less than 200 nm. Relationships between solvents and excipients used and their amount are discussed. Based on the results the investigated solvent evaporation methods can be used as an effective and an affordable technique for the preparation of nanoparticles. MDPI 2012-11-06 /pmc/articles/PMC6268062/ /pubmed/23132139 http://dx.doi.org/10.3390/molecules171113221 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Vaculikova, Eliska
Grunwaldova, Veronika
Kral, Vladimir
Dohnal, Jiri
Jampilek, Josef
Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
title Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
title_full Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
title_fullStr Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
title_full_unstemmed Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
title_short Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
title_sort preparation of candesartan and atorvastatin nanoparticles by solvent evaporation (†)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268062/
https://www.ncbi.nlm.nih.gov/pubmed/23132139
http://dx.doi.org/10.3390/molecules171113221
work_keys_str_mv AT vaculikovaeliska preparationofcandesartanandatorvastatinnanoparticlesbysolventevaporation
AT grunwaldovaveronika preparationofcandesartanandatorvastatinnanoparticlesbysolventevaporation
AT kralvladimir preparationofcandesartanandatorvastatinnanoparticlesbysolventevaporation
AT dohnaljiri preparationofcandesartanandatorvastatinnanoparticlesbysolventevaporation
AT jampilekjosef preparationofcandesartanandatorvastatinnanoparticlesbysolventevaporation